Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

34
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
34

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Reduction in Acetylation of Superoxide Dismutase 2 in Skeletal Muscle Improves Exercise Capacity in Mice With Heart Failure.

Journal of cachexia, sarcopenia and muscle·2025
Same author

Clinical characteristics and outcomes of hospitalized patients with heart failure from the Japanese prospective registry.

Journal of cardiology·2025
Same author

Prognostic impact of moderate to severe anemia associated with renal dysfunction in patients with heart failure.

Scientific reports·2025
Same author

Nationwide Temporal Trends in Clinical Characteristics and Treatment of Dilated Cardiomyopathy From 2003 to 2013 in Japan　- A Report From Clinical Personal Records.

Circulation journal : official journal of the Japanese Circulation Society·2023
Same author

Fulminant necrotizing eosinophilic myocarditis after COVID-19 vaccination survived with mechanical circulatory support.

ESC heart failure·2022
Same author

Effectiveness of statin intensive therapy in type 2 diabetes mellitus with high visit-to-visit blood pressure variability.

Journal of hypertension·2021

関連する実験動画

Updated: Sep 9, 2025

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
10:18

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model

Published on: June 29, 2014

17.2K

GOREISANは,ICAT-β-カテニン/ERK軸の調節により,HFD/L-NAMEによって誘発された保存されたエジェクション分数による心不全における心筋縮および腹動機能障害を緩和する.

Yoko Shojima Isayama1,2, Shouji Matsushima3,4, Keisuke Shinohara1,2

  • 1Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.

Hypertension research : official journal of the Japanese Society of Hypertension
|September 3, 2025
PubMed
まとめ
この要約は機械生成です。

Goreisan (GRS) は,心筋縮と腹動機能不全を軽減することによって,心筋縮を保存した心筋縮 (HFpEF) を効果的に治療します. この薬草は,ICAT-β-カテニン/ERK経路を標的とし,潜在的な治療の選択肢を提供します.

キーワード:
ゴレーザン心臓の大幅縮小ディアストリック機能不全発射分子が保存された心不全

さらに関連する動画

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

10.1K
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

287

関連する実験動画

Last Updated: Sep 9, 2025

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
10:18

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model

Published on: June 29, 2014

17.2K
A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

10.1K
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

287

科学分野:

  • 心血管研究
  • 薬理学について
  • 中国 伝統 医学

背景:

  • 保存されたエジェクション分数 (HFpEF) による心不全は,心筋縮と腹筋機能不全によって特徴づけられる世界的な健康上の懸念事項です.
  • ゴレーサン (Goreisan,GRS) のような伝統的なハーブ製薬は,心臓血管疾患における治療の可能性について調査されています.

研究 の 目的:

  • 保存されたエジェクション分数 (HFpEF) の心不全の病理生理学的改善におけるGoreisan (GRS) の有効性を調査する.
  • GRSが心筋縮と腹動機能不全に及ぼす影響の分子メカニズムを解明する.

主な方法:

  • HFpEFのマウスモデルは,高脂肪食 (HFD) とN-ニトロ-L-アルギニンメチレスター (L-NAME) を使用して確立されました.
  • 心臓と肺の重量,心室壁の厚さ,腹動機能指数 (E/ A,E/ E'),および心筋細胞のサイズに対するGRS治療の効果を評価した.
  • 分子分析には,ミトゲン活性化タンパク質キナーゼ (MAPK) のためのウエスタン・ブロッティングと,タンパク質プロファイルのための液体染色体/質量スペクトロメトリー (LC-MS) が含まれていた.
  • GRSの直接的作用とICAT,β-カテニン,ERKの役割を調べるために,インビトロ試験では,イソプロテレノール (ISO) 治療を受けた心筋細胞を使用した.

主要な成果:

  • GRS投与は,HFD/ L- NAMEで治療されたマウスにおいて,心臓と肺の重量を有意に減らし,心筋縮と静脈機能不全を弱めた.
  • GRSは細胞外信号調節キナーゼ (ERK) のリン酸化を抑制し,β- カテニン増殖阻害剤 (ICAT) を含む73のタンパク質の発現を調節した.
  • この効果はICAT過剰発現によって模倣され,部分的にシナマルデヒドとアリゾールB23酸性酸に起因する.

結論:

  • HFpEFの重要な特徴である心臓高縮および腹動機能不全を緩和する有意な可能性を示しています.
  • GRSの治療効果は,ICAT-β-カタニン/ERKシグナル伝達経路によって媒介されます.
  • GRSはHFpEFの管理に有望なハーブ療法候補である.